股票代码：600381 股票简称：ST 春天 公告编号：2024-021 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 青海春天药用资源科技股份有限公司（以下简称"公司"）子公司成都听花盛世贸 易有限公司（以下简称"听花盛世"）于 2024 年 4 月 25 日收到成都市武侯区市场监督 管理局（以下简称"武侯区市监局"）成武市监罚告[2024]-51-03 号《行政处罚告知书》 （详见公司 2024 年 4 月 26 日披露的 2024-011 号公告）。听花盛世于近日收到武侯区 市监局成武市监处罚[2024]-51-03 号《行政处罚决定书》，现将主要内容公告如下： 一、《行政处罚决定书》的主要内容 1. 当事人 青海春天药用资源科技股份有限公司 关于全资子公司收到《行政处罚决定书》的公告 名称：成都听花盛世贸易有限公司 住所：成都市武侯区人民南路四段 46 号 1 楼附 17 号 统一社会信用代码：91510107572293267Y 2. 违法情况 当事人在销售听花系列白酒的过程中，使用科学上未定论的观点和"听花"酒未 ...

对青海春天药用资源科技股份有限公司 《问询函》的回复 青海春天药用资源科技股份有限公司： 贵公司关于股票交易异常波动的《问询函》我公司已收悉。我公 司就该《问询函》所关注事项回复、确认如下： 截至本回函日,我公司不存在其他买卖贵公司股票的情况、不存 在涉及贵公司的应披露而未披露的重大事项,包括但不限于筹划重大 资产重组、股份发行、债务重组、业务重组、资产剥离和资产注入等 重大事项。 专此回复。 西藏荣恩科技有限公司 《问询函》的回复 青海春天药用资源科技股份有限公司: 本人已收到贵司关于股票交易异常波动的《问询函》,并就该《问 询函》所关注事项回复、确认如下: 截至本回复日,本人不存在买卖贵公司股票、不存在涉及贵公司 的应披露而未披露的重大事项,包括但不限于筹划重大资产重组、股 份发行、债务重组、业务重组、资产剥离和资产注入等重大事项。 专此回复。 回复人:肖融 2024年5月8日 r 17 对青海春天药用资源科技股份有限公司 ...

股票代码：600381 股票简称：ST 春天 公告编号：2024-020 青海春天药用资源科技股份有限公司 关于股票交易异常波动的公告 （一）生产经营情况 公司于 2024 年 4 月 30 日披露了公司《2023 年年度报告》和《2024 年第一季度报 告》，公司 2023 年度实现营业收入为 21,387.67 万元，归属于上市公司股东的净利润- 26,786.53 万元；2024 年第一季度实现营业收入为 8,449.94 万元，归属于上市公司股 东的净利润为-2,690.51 万元，公司生产经营情况正常。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 青海春天药用资源科技股份有限公司（以下简称"公司"）股票交易在 2024 年 5 月 6 日、7 日、8 日连续 3 个交易日内日收盘价格跌幅偏离值累计达到 12%，属于股 票交易异常波动。 经公司自查及向公司控股股东、实际控制人发函核实、确认，截至本公告披露 日，除公司已披露事项外，不存在其它应披露而未披露的重大事项。 请广大投资者理性投资，注意股票二 ...

股票代码：600381 股票简称：ST 春天 公告编号：2024-019 青海春天药用资源科技股份有限公司 关于以集中竞价交易方式首次回购公司股份暨回购进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2024 年 5 月 6 日，青海春天药用资源科技股份有限公司（以下简称"公司"）通过 集中竞价交易方式首次回购股份 100 万股，占公司总股本的 0.17%，首次回购股份的成 交价为 4.31 元/股，成交总金额为 431 万元（不含交易佣金等交易费用）。 一、 回购股份的基本情况 公司于 2024 年 4 月 18 日召开第九届董事会第五次会议，审议通过了《关于以集 中竞价交易方式回购公司股份的议案》。拟使用不低于人民币 3,000 万元（含）且不超 过人民币 5,000 万元（含）自有资金以集中竞价交易方式回购公司股份，用于维护公 司价值及股东权益。本次回购期限为自 2024 年 4 月 18 日起不超过 3 个月。 本次回购公司股份方案的具体内容详见公司于 2024 年 4 月 19 日披露的《 ...

Financial Performance - The company's consolidated net profit attributable to shareholders for 2023 was -267,865,267.06 CNY, while the parent company's net profit was 40,096,770.34 CNY[6]. - Total operating revenue for 2023 reached 213,876,676.45 CNY, representing a 33.52% increase compared to 160,178,078.61 CNY in 2022[22]. - The net cash flow from operating activities was 23,916,780.35 CNY, a significant improvement from -31,821,162.74 CNY in the previous year[23]. - Basic earnings per share for 2023 were -0.46 CNY, slightly improved from -0.49 CNY in 2022[24]. - The weighted average return on equity was -19.15% for 2023, a decrease of 2.00 percentage points from -17.15% in 2022[24]. - The company reported a net profit attributable to shareholders of the listed company was -267.87 million RMB, with a net profit of -243.67 million RMB after deducting non-recurring gains and losses[34]. - The company incurred impairment losses totaling 15.16 million RMB, including 1.16 million RMB for impairment losses and 11.69 million RMB for long-term equity investment losses[34]. - The company reported a cash flow from operating activities of -276.87 million RMB for the year[27]. - The company reported a significant increase in the provision for inventory impairment, amounting to CNY 7,868.24 million, which is critical for financial statement accuracy[184]. Revenue Breakdown - The company reported a decrease in total revenue from non-core business activities, with the adjusted operating revenue at 206,784,656.28 CNY, up 33.37% from 155,045,737.02 CNY in 2022[22]. - The company achieved a revenue of 206.78 million RMB after excluding non-main business income, reflecting a growth of 33.37%[34]. - The health business segment generated a revenue of 123.84 million yuan, representing a year-on-year growth of 101.68%[38]. - Revenue from the sales of Cordyceps sinensis reached 38.93 million yuan, with a year-on-year increase of 97.50%[38]. - The sales of the traditional Chinese medicine product "Lifelong Tablets" achieved revenue of CNY 84.91 million, marking a year-on-year increase of 103.66%[49]. - The overall revenue from the main business reached 206.78 million yuan, a year-on-year increase of 33.37%[43]. - The liquor business segment generated revenue of 83.83 million yuan, accounting for 39.20% of the total revenue, with total assets related to this segment amounting to 333.70 million yuan, representing 24.55% of total assets[180]. Expenses and Costs - The sales expenses increased by 47.79 million RMB compared to the previous year, impacting the overall profitability despite revenue growth[34]. - The company's sales expenses amounted to 171.03 million yuan, reflecting a year-on-year increase of 38.78%[38]. - The operating costs for the reporting period were CNY 82.96 million, a year-on-year decrease of 3.89%[51]. - Total operating costs increased to RMB 322,080,094.07, up 11.0% from RMB 289,917,807.91 in the previous year[197]. - Sales expenses surged to RMB 171,034,609.99, a 38.8% increase from RMB 123,243,606.03 in the previous year[197]. Assets and Liabilities - The total assets at the end of 2023 were 1,359,312,015.51 CNY, down 12.82% from 1,559,229,152.99 CNY at the end of 2022[23]. - The company's net assets attributable to shareholders decreased by 17.47% to 1,265,066,305.34 CNY from 1,532,931,572.40 CNY in 2022[23]. - The total current assets decreased to CNY 749,237,778.13 from CNY 816,003,528.06, indicating a reduction of approximately 8.2%[190]. - Current liabilities increased significantly from ¥21,725,357.71 in 2022 to ¥81,144,349.05 in 2023, representing an increase of about 272.5%[191]. - Total liabilities increased from ¥26,298,977.83 in 2022 to ¥91,994,257.88 in 2023, representing an increase of approximately 249.5%[191]. Strategic Initiatives - The company focused on the fast-moving consumer goods and health sectors, enhancing product quality and expanding sales channels[33]. - The company is accelerating the construction and operation of its liquor experience stores, aiming to enhance market presence and consumer engagement[34]. - The company plans to continue focusing on product promotion and market expansion strategies to enhance revenue growth in the upcoming periods[87]. - The company aims to leverage its R&D and marketing strengths to align with the growing demand for high-quality and innovative liquor products[41]. - The company is actively pursuing market expansion and product development in response to the supportive policies for the TCM industry[78]. Governance and Compliance - The company has established comprehensive internal governance regulations but acknowledges the need for ongoing improvements to adapt to external changes and ensure effective execution[105]. - The board of directors has completed its restructuring, establishing four specialized committees to ensure compliance with governance regulations and protect shareholder rights[110]. - The company maintains independence in operations and decision-making from its controlling shareholders, ensuring no non-operational use of company funds[113]. - The company has not faced any penalties from securities regulatory authorities in the past three years[128]. - The company is committed to transparency and accountability, as evidenced by the detailed reporting of board activities and remuneration[120]. Environmental and Social Responsibility - The company invested 1.0575 million yuan in environmental protection during the reporting period[148]. - The company actively participates in environmental protection activities, including World Environment Day events[148]. - The company emphasizes a culture of integrity, focusing on investor interests, product quality, environmental protection, and community engagement[152]. - The company has implemented carbon reduction measures, including using solar energy for boiler water preheating, which has reduced carbon emissions from gas usage[150]. Risks and Challenges - The company has acknowledged various risks in its future development plans, urging investors to be cautious[9]. - The competitive landscape in the liquor market is intense, with strong consumer demand for quality, which may affect revenue and profit if marketing strategies are not effectively executed[105]. - The company faces risks from international political and economic environments that may impact domestic industry and market conditions, leading to uncertainties in strategic development and operational plans[105].

Financial Performance - The company's operating revenue for Q1 2024 was CNY 84,499,399.27, representing a year-on-year increase of 49.96% primarily due to growth in beverage and Cordyceps sinensis business[5] - The net profit attributable to shareholders of the listed company was a loss of CNY 26,905,064.87, with basic and diluted earnings per share both at -0.0458 yuan[5] - The net profit for Q1 2024 was -25,962,451.61 RMB, an improvement from -27,835,471.27 RMB in Q1 2023, representing a decrease in net loss of approximately 6.3%[18] - Operating profit for Q1 2024 was -23,788,381.41 RMB, compared to -27,451,702.32 RMB in Q1 2023, indicating a reduction in operating loss of about 13.3%[18] - The total comprehensive loss for Q1 2024 was -25,962,451.61 RMB, compared to -27,835,471.27 RMB in Q1 2023, indicating a reduction in comprehensive loss of about 6.3%[19] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 13,863,768.33, indicating a positive cash flow despite the net loss[5] - Cash flow from operating activities generated a net inflow of 13,863,768.33 RMB in Q1 2024, a significant recovery from a net outflow of -27,687,230.10 RMB in Q1 2023[23] - Cash and cash equivalents as of March 31, 2024, amounted to ¥182,529,839.73, an increase from ¥172,259,633.41 as of December 31, 2023[13] - The cash and cash equivalents at the end of Q1 2024 stood at 182,529,839.73 RMB, an increase from 140,098,797.46 RMB at the end of Q1 2023, representing a growth of approximately 30.3%[24] - The cash flow from investing activities resulted in a net outflow of -2,181,622.15 RMB in Q1 2024, compared to -811,156.74 RMB in Q1 2023, indicating an increase in investment outflow[23] Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 1,295,456,592.55, down 4.70% from the end of the previous year[6] - Total assets as of March 31, 2024, were ¥1,295,456,592.55, down from ¥1,359,312,015.51 at the end of 2023[16] - Total liabilities decreased to ¥54,101,286.53 from ¥91,994,257.88, a reduction of approximately 41%[15] - Shareholders' equity attributable to the listed company decreased by 2.13% to CNY 1,238,161,240.47 compared to the end of the previous year[6] Operational Metrics - Total operating revenue for Q1 2024 reached ¥84,499,399.27, a significant increase of 50% compared to ¥56,346,354.72 in Q1 2023[17] - Total operating costs for Q1 2024 were ¥108,529,464.19, up from ¥84,161,826.81 in Q1 2023, reflecting a 29% increase[17] - The company's gross profit margin decreased, with gross profit for Q1 2024 at ¥45,850,000.00, compared to ¥36,000,000.00 in Q1 2023[17] - The company incurred operating expenses of 71,094,754.38 RMB in Q1 2024, down from 76,852,343.62 RMB in Q1 2023, showing a decrease of approximately 7.5%[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 61,429, with the largest shareholder holding 32.1% of the shares[10] Research and Development - The company reported R&D expenses of ¥1,191,317.83 for Q1 2024, a decrease from ¥2,036,313.84 in Q1 2023, reflecting a 41% reduction[17] Future Outlook - The company plans to continue expanding its product lines and market presence, focusing on innovative product development[8] - The management emphasized the importance of cash flow management in light of the current financial performance and market conditions[8] Non-Recurring Items - Non-recurring gains and losses amounted to CNY 80,061.31, with significant contributions from government subsidies and asset disposals[8] - The company reported investment income of 58,635.62 RMB in Q1 2024, compared to 38,652.91 RMB in Q1 2023, reflecting a growth of about 51.8%[23]

青海春天药用资源科技股份有限公司 关于全资子公司收到《行政处罚告知书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 青海春天药用资源科技股份有限公司（以下简称"公司"）子公司成都听花盛世贸 易有限公司（以下简称"听花盛世"）于 2024 年 4 月 25 日收到成都市武侯区市场监督 管理局（以下简称"武侯区市监局"）成武市监罚告[2024]-51-03 号《行政处罚告知书》。 现将有关内容公告如下： 一、《行政处罚告知书》的主要内容 成都听花盛世贸易有限公司: 由本局立案调查的你公司涉嫌虚假宣传一案，已调查终结。依据《中华人民共和 国行政处罚法》第四十四条的规定，现将本局拟作出行政处罚的内容及事实、理由、 依据告知如下: 经查实，你公司在经营场所销售"听花"酒过程中，存在将"听花"酒功效中科 学上未定论的观点和未经核实的用户评价用于"听花"酒的商品宣传，作引人误解的 宣传行为，且情节严重。你公司上述行为违反了《中华人民共和国反不正当竞争法》 第八条第一款"经营者不得对其商品的性能、功能、质量、销售状况、用户评价、曾 ...

| 序号 | 股东名称 | 持股数量（股） | 持股比例（%） | | --- | --- | --- | --- | | 1 | 西藏荣恩科技有限公司 | 188,615,194 | 32.13 | | 2 | 肖融 | 56,762,789 | 9.67 | | 3 | 上海稻满私募基金管理有限公司－稻满 号私募证 2 券投资基金 | 5,110,000 | 0.87 | | 4 | 卢义萍 | 3,946,857 | 0.67 | | 5 | 杜敬习 | 3,428,690 | 0.58 | | 6 | 陈德兴 | 3,303,300 | 0.56 | | 7 | 香港中央结算有限公司 | 2,970,133 | 0.51 | | 8 | 上海稻满私募基金管理有限公司－稻满 8 号私募证 | 2,640,000 | 0.45 | | | 券投资基金 | | | | 9 | 詹晓康 | 2,410,000 | 0.41 | | 10 | 岳凌龙 | 1,915,800 | 0.33 | 青海春天药用资源科技股份有限公司 关于回购股份事项前十大股东和前十大无限售条件 股东持股情况的公告 本公司董事会及全体董 ...

证券代码：600381 证券简称：青海春天 公告编号：2024-009 青海春天药用资源科技股份有限公司 关于以集中竞价交易方式回购股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2.如对公司股票交易价格产生重大影响的重大事项发生，或公司生产经营、财 务状况、外部客观情况发生重大变化，或其他可能导致公司董事会决定终止本回购 方案等事项发生，则存在回购方案无法顺利实施或需要调整的风险。 3.本次回购股份将在披露回购结果暨股份变动公告十二个月后采用集中竞价 交易方式出售，若公司未能在规定期限内完成出售，则存在变更用途的风险。如未 使用部分依法注销，存在债权人要求公司提前清偿债务或要求公司提供相应担保 重要内容提示： ● 回购股份金额：回购资金总额不低于人民币 3,000 万元（含）,不超过人民 币 5,000 万元（含）。 ● 回购股份资金来源：公司自有资金。 ● 回购股份用途：为维护公司价值及股东权益，所回购股份根据规定将用于后 续出售。 ● 回购股份价格：不高于董事会审议通过本回购股份决议前 30 个交易 ...

证券代码：600381 证券简称：青海春天 公告编号：2024-007 青海春天药用资源科技股份有限公司 关于以集中竞价交易方式回购股份的方案 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份金额：回购资金总额不低于人民币3,000万元（含）,不超过人 民币5,000万元（含）。 ● 回购股份资金来源：公司自有资金。 ● 回购股份用途：为维护公司价值及股东权益，所回购股份根据规定将用 于后续出售。 ● 回购股份价格：不高于董事会审议通过本回购股份决议前30个交易日公 司股票交易均价的150%，即不超过8.19元/股。 ● 回购股份方式：采用集中竞价交易方式。 ● 回购股份期限：自公司董事会审议通过本次回购方案之日起不超过 3 个 月。 ● 相关股东是否存在减持计划：经公司问询，截至董事会审议通过本次回 购方案之日，公司董监高、控股股东、实际控制人、持股 5%以上的股东在未来 3 个月、未来 6 个月暂无明确减持公司股票的计划。上述主体如未来有减持计划， 相关方及公司将严格按照有关法律、法规及规范 ...